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Background. Although herbal medicines are used by patients with cancer in multiple oncology care settings, the magnitude of
herbal medicine use in this context remains unclear. )e purpose of this review was to establish the prevalence of herbal medicine
use among patients with cancer, across various geographical settings and patient characteristics (age and gender categories).
Methods. Electronic databases that were searched for data published, from January 2000 to January 2020, wereMedline (PubMed),
Google Scholar, Embase, and African Index Medicus. Eligible studies reporting prevalence estimates of herbal medicine use
amongst cancer patients were pooled using random-effects meta-analyses. Studies were grouped by World Bank region and
income groups. Subgroup and meta-regression analyses were performed to explore source of heterogeneity. Results. In total, 155
studies with data for 809,065 participants (53.95% female) met the inclusion criteria. Overall, the pooled prevalence of the use of
herbal medicine among patients with cancer was 22% (95% confidence interval (CI): 18%–25%), with the highest prevalence
estimates for Africa (40%, 95% CI: 23%–58%) and Asia (28%, 95% CI: 21%–35%). )e pooled prevalence estimate was higher
across low- and middle-income countries (32%, 95% CI: 23%–42%) and lower across high-income countries (17%, 95% CI: 14%–
21%). Higher pooled prevalence estimates were found for adult patients with cancer (22%, 95% CI: 19%–26%) compared with
children with cancer (18%, 95% CI: 11%–27%) and for female patients (27%, 95% CI: 19%–35%) compared with males (17%, 95%
CI: 1%–47%). Conclusion. Herbal medicine is used by a large percentage of patients with cancer use. )e findings of this review
highlight the need for herbal medicine to be integrated in cancer care.
1. Introduction
Cancer is a major global health problem. In 2018, there were
an estimated 9.6 million cancer fatalities and 18.1 million
newly diagnosed cases [1]. Current trends indicate that the
previously predicted increase to 20 million new cases by
2025 is likely to be surpassed [2]. )e overall implications of
this high rate of new cases of cancer include increased health,
economic, and social costs, which will continue to put a
burden on the limited resources and weak healthcare sys-
tems in poor countries. As a result, herbal (traditional)
medicines use in cancer care may be increased in those
countries.
Herbal medicine use associated with cancer, including in
multiple oncology care settings, remains uncontested [3].
Previous studies have indicated that herbal medicine is the
commonest form of complementary and alternative medi-
cine (CAM) used by patients with cancer, with increasing
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use following a cancer diagnosis [4–12]. Furthermore, ad-
vances in conventional cancer care have not deterred pa-
tients with cancer from using herbal medicines for
numerous reasons, including patient- or disease-related
factors, cultural and historical factors, geographical or to-
pological factors, and healthcare or system-related factors
[11, 13–21].
Several studies have identified and documented the
clinical (cancer disease) and individual (demographic)
factors associated with the usage of herbal medicine in
cancer. Numerous factors have been positively correlated
with herbal medicine use in cancer, such as young age, high
education level, high-income level, ethnicity, female gender,
cancer diagnosis, longer survival period since cancer diag-
nosis, receiving single or multiple cancer chemotherapies,
being married, completion of conventional cancer treat-
ment, having certain cancer symptoms, cancer metastasis,
and belonging to specific social groups [22–27]. However,
old age, being a child, having cancer comorbidities, place of
residence, and the experience of chemotherapeutic side
effects are negatively associated with herbal medicine use in
cancer [16, 26, 28].
Some herbal medicines possess compounds that are
pharmacologically active against cancer cells, and preclinical
studies have consistently shown that numerous herbal
medicines or herbs have antiapoptotic, anti-inflammatory,
cell regenerative, and antioxidant effects on cancer cells.
However, the clinical evidence concerning the efficacy of most
herbal medicines or specific herbs used in cancer is largely
inconclusive [29, 30]. Clinical studies have reported that the
use of herbal medicines in cancer lowered the mortality rate
hazard ratio of patients with lung cancer (thereby increasing
survival), improved patients’ quality of life through reducing
cancer symptoms and conventional drug side effects (e.g.,
nausea and vomiting), and had chemopreventive activity
against certain cancers [17, 19, 31, 32].
Conversely, observational studies have indicated that
concomitant herbal medicines use with antineoplastic drugs
may result in drug to herb interaction (at all pharmacokinetic
and pharmacodynamics levels) and adverse side effects or
events [9, 31, 33, 34]. Adverse side effects or events range from
minor side effects (e.g., gastrointestinal distress and allergy) to
severe organ failure (e.g., hepatotoxicity, nephrotoxicity, bone
marrow suppression, and respiratory and cardiac failure)
[31, 32, 35–37]. Importantly, the release of antioxidants by
herbal medicines is thought to reduce the oxidizing free
radicals created by radiotherapy and chemotherapeutic agents
against cancer cells, potentially reducing the effectiveness of
conventional cancer treatment [24, 38]. Similarly, herbs
commonly used in cancer such as St. John’s wort and grape
juice induce cytochrome isoenzymes (especially CYP3A4),
which metabolize most conventional anticancer agents,
thereby reducing the efficacy of targeted therapies such as
tyrosine kinase inhibitors and anticancer hormonal therapies
[31, 32, 38]. St. John’s wort, specifically, was found to reduce
the levels of plasma irinotecan, docetaxel, and imatinib
mesylate antichemotherapeutic agents’ concentrations [31].
Additionally, other herbs commonly used in cancer have been
found to cause bleeding tendencies following surgery (e.g.,
ginkgo, garlic), hypoglycemia (e.g., ginseng), and hepato-
toxicity (e.g., kava) and possess carcinogenic or negative
tumor moderating effects [4, 35, 39]. In addition, heavy metal
contamination in some herbal medicines may alter the
pharmacokinetic profile of commonly used conventional
cancer treatments [24, 38, 40].
Despite the widespread herbal medicines use among
cancer patients, associated factors, and potential benefits and
risks, the overall pooled prevalence of the use of herbal
medicines among patients with cancer remains unclear.
Previous systematic reviews focused on cancer used quali-
tative (narrative synthesis) designs and focused on syn-
thesizing primary data on the use of CAM treatment
modalities in general [41–47]. )erefore, we conducted a
meta-analysis to explore the prevalence of the use of herbal
medicine among patients with cancer across various geo-
graphical settings and patient characteristics and synthesized
the literature on commonly used herbs in cancer. Under-
standing the prevalence of herbal medicine use by patients
with cancer may help inform and guide healthcare policies
geared toward integrating herbal medicines use in cancer
care. Ultimately, this will help to improve outcomes for
patients with cancer, develop wider public health (com-
munity) policies around herbal medicine legislation, and
promote investment in education and research about herbal
medicines used in cancer.
2. Methods
2.1. Protocol Registration. PROSPERO guidelines were used
to develop this study protocol. )e study protocol was
subsequently registered with the open source foundation
(doi: 10.31730/osf.io/cbtpy). )e Preferred Reporting Items
for Systematic Reviews and Meta-Analyses (PRISMA)
guidelines are used to report this review’ findings (https://
www.prisma-statement.org, Supplementary Table 1).
2.2. Eligibility Criteria. We synthesized hospital- and pop-
ulation-based studies that reported the prevalence of the use
of herbal medicines among patients with cancer (Table 1).
2.3. Information Sources and Search Strategy. We searched
PubMed, Google Scholar, Embase, and African Index
Medicus for articles published from January 2000 to January
2020.)e key search terms words that were used to guide the
search included the following: “Cancer” OR “Neoplasm” OR
“Tumo∗ ” OR “Malignancy” AND “Herbs” OR “Herbal
medicine” OR “Herbal material” OR “Herbal preparation”
AND “Prevalence” OR “Use” OR “Proportion” OR
“Percent∗ ” AND “Observational studies” OR “Cohort” OR
“Cross-sectional∗ ” OR “Survey” OR “Cohort” (Supple-
mentary Table 2). In addition, we manually skimmed the
references of published review articles and primary studies
to obtain any further eligible studies.
2.4. Data Extraction: Selection and Coding. After obtaining
relevant studies (A.J.B), two authors (P.P.N and A.M.S)
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screened the identified articles’ abstracts and titles and
determined their eligibility for inclusion in this review,
independently. Two authors (J.B.A and A.M.S) indepen-
dently extracted the data using a standard data extraction
form or tool created in Microsoft Excel 2016. Before data
were extracted, the data extraction tool was pilot tested with
10 studies. Following the findings of the pilot test, im-
provements to the data extraction tool were made after
reaching consensus with all reviewers. )e extracted data
included the following: (i) methodological or study char-
acteristics, (ii) herbal medicine definitions or terms used,
(iii) the focus of study (herbal medicine only or with other
CAM modalities), (iii) use of conventional treatment, (iv)
gender distribution, (v) participants’ average age, (vi) sample
size, (vii) proportion or frequency of herbal medicine use,
(viii) herbs used in cancer, and (ix) conclusions. Countries
were categorized by continent or world regions and
according to World Bank economic indicators (Supple-
mentary Table 3). )e authors were able to resolve dis-
agreements during data extraction through consensus.
2.5. Risk of Bias Assessment. Using the risk of bias of non-
randomized studies (RoBINS) tool, three authors (J.B.A,
A.M.S, and P.P.N) independently assessed and reported the
risk of bias in selected studies [48–50]. )e risk of bias was
categorized as high, moderate (unclear), and low across the
various categories of bias (participation bias, selection bias,
and confounder bias) (Supplementary Tables 4 and 5).
2.6.DataAnalysis andSynthesis. )emetaprop command in
Stata software (version 12) was used to analyze the data.
Freeman–Tukey double arcsine transformation was used to
“stabilize the raw proportions” [51]. )e pooled prevalence
estimates and their confidence intervals (CI) were computed
using the DerSimonian and Laird random-effects model
(DL) and Wald method, respectively, based on “the trans-
formed values and their variances” [51]. We inspected the
forest plots for heterogeneity and then quantified this using
chi-square tests and the I2 statistic. Because of significant
heterogeneity (>50%), we explored the possible modifying
effects of a number of study-level variables on the overall
pooled prevalence of herbal medicine use among patients
with cancer based on subgroup and meta-regression ana-
lyses [52, 53]. Modifying variables included the following: (i)
year of publication (before or after 2010), (ii) study focus
(herbal medicine alone vs. herbal medicine with other
CAM), (iii) data collection method (researcher-adminis-
tered vs. self-administered vs. document or record reviews),
(iv) country income level (low and middle vs. high income),
(v) study setting (hospital vs. community), (vi) study pop-
ulation (adults vs. children), (vii) cancer type (breast vs.
prostate vs. hematological vs. others), (viii) region (conti-
nent), (ix) World Bank subregion, (x) study design (cross-
sectional vs. cohort), and (xi) study country. We evaluated
publication bias by inspecting the funnel plot for asymmetry
and confirmed it using Egger’s regression test [54]. We also
reported the weighted pooled prevalence estimates and their
95% CIs. Data related to herbs used by patients with cancer
were summarized and described.
3. Results
3.1. Study Selection Flow. In total, 6414 studies were re-
trieved from various search engines and databases (Fig-
ure 1). After eliminating duplicates, 4882 articles were
selected for critical screening of the titles and abstracts. )e
final meta-analysis included 153 full-text articles that met
the inclusion criteria. Eighty-six (86) articles were included
in the qualitative synthesis of commonly used herbs by
patients with cancer.
3.2. Study Characteristics. Characteristics of the included
studies, which involved 809,065 participants (53.95% fe-
male) from 44 countries, are given in Table 2. )e average
age of the study participants was 50.98± 17.39 years, and the
average response rate was 76.95%± 19.78%. )e majority of
studies were conducted in America (34.19%), Europe
(30.32%), and Asia (29.68%). However, based on World
Bank subregions, most studies were carried out in Europe
and Central Asia (32.92%), North America (30.32%), and
East Asia and the Pacific (23.23%). )e majority of the
included primary research studies were from high-income
countries (65.77%), with the US at the top of the list of
Table 1: Inclusion and exclusion criteria for included studies.
Inclusion criteria Exclusion criteria
Participants Female and male participants of all ages suffering from cancer using herbalmedicine(s) with or without any other CAM remedy(s) or conventional remedy(s). Cancer survivors (recovered)
Outcomes Prevalence of herbal medicine use (either reported or self-reported)Herbs commonly used by patients with cancer Prevalence not reported









Studies that were approved by an ethical review body or committee and
participants consented to participate.
Lack of ethical approval and
participant consent
Language Published in the English language Published in any other language
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individual countries (27.10%). Most studies used cross-
sectional designs (99.35%), focused on studying herbal
medicine as part of other CAM modalities (92.26%), and
were conducted in hospital settings (85.81%) among adult
populations (83.23%). Most participants were recruited
using convenience sampling techniques (63.87%). )e most
common data collection method was self-administered in-
terviews (52.90%), and the most common cancer type was
breast cancer (18.71%).
3.3. Overall Pooled Prevalence of Herbal Medicine Use in
Cancer by Income and Region. In total, 155 studies reported
crude prevalence estimates of herbal medicine use by pa-
tients with cancer [3–40, 55–168]. )e prevalence estimates
ranged from 1% (95% CI: 0%-1%) to 93% (95% CI: 92%-
93%). )e overall random-effects pooled prevalence of
herbal medicine use by patients with cancer was 22% (95%
CI: 18%–25%, Figure 2). )e I2 statistic was 99.84% (χ2
(df� 154)� 96436.14, P≤ 0.001), indicating considerable
heterogeneity among the included studies. On inspection,
the funnel plot was symmetrical, as confirmed by Egger’s
regression test (P � 0.063), indicating the absence of small-
study effects (publication bias).
In terms of continents, the largest pooled prevalence of
herbal medicine use among patients with cancer was found
in Africa (40%, 95% CI: 23%–58%) and Asia (28%, 95% CI:
21%–35%, Figure 2). )e lowest prevalence was recorded in
Oceania (9%, 95% CI: 4%–15%). Analysis by subregion
showed the highest prevalence of herbal medicine use
among patients with cancer was in sub-Saharan Africa (40%,
95% CI: 23%–58%), followed by the Middle East (36%, 95%
CI: 19%–54%), Latin America and the Caribbean (35%, 95%
CI: 23%–48%), East Asia and the Pacific (21%, 95% CI: 14%–
29%), North America (20%, 95% CI: 16%–24%), and Europe
and Central Asia (19%, 95% CI: 15%–23%). Among selected
countries (with n≥ 3 studies), the highest pooled prevalence
of herbal medicine use by patients with cancer was in
Palestine (69%, 95% CI: 59%–77%, n� 4), followed by China
(58%, 95% CI: 45%–71%, n� 7), Turkey (33%, 95% CI: 22%–
44%, n� 18), Taiwan (24%, 95% CI: 9%–42%, n� 7), Canada
(21%, 95% CI: 11%–33%, n� 5), South Korea (21% 95% CI:
7%–40%, n� 3), the US (19%, 95% CI: 15%–24%, n� 42),
mixed European countries (15%, 95% CI: 11%–18%, n� 6),
Germany (12%, 95%CI: 6%–19%, n� 5),)ailand (12%, 95%
CI: 0%–38%, n� 3), Malaysia (10%, 95% CI: 5%–17%, n� 5),
the UK (8%, 95% CI: 3%–14%, n� 9), and Australia (8%,
95% CI: 3%–16%, n� 5). Finally, the pooled prevalence of
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Figure 1: Study selection process based on PRISMA (https://www.prisma-statement.org).
4 Evidence-Based Complementary and Alternative Medicine
herbal medicine use in treating cancer was higher among
patients from low- and middle-income countries (32%, 95%
CI: 23%–42%) compared with high-income countries (17%,
95% CI: 14%–21%).
3.4. Overall Subgroup and Meta-Regression Analyses. We
conducted subgroup and meta-regression analyses to in-
vestigate the influence of various patient and study char-
acteristics on the overall observed prevalence estimates to
explore the heterogeneity observed among the included
studies. )e subgroup analyses indicated that geographical
region (P≤ 0.001), subregion (P≤ 0.001), income group
(P≤ 0.001), study focus or type (P≤ 0.001), study country
(P≤ 0.001), and study design (P≤ 0.001) had statistically
significant moderating effects on the overall pooled preva-
lence of herbal medicine usage in cancer.
Conversely, in the bivariate meta-regression analysis,
only three variables were related to the overall pooled
prevalence of usage of herbal medicine by cancer patients.
Visual inspection of the scatter plot showed that studies that
investigated herbal medicine in conjunction with other
CAM modalities in cancer (20%, 95% CI: 16–23%) were
more than twice less likely to report a higher pooled
prevalence than studies that focused on herbal medicine use
alone (48%, 95% CI: 35%–61%; β� −1.47, 95% CI: −2.18
to −0.76; P≤ 0.001; Figure 3(a)). In addition, studies from
high-income countries were less likely to report a high
pooled prevalence of herbal medicine use in cancer com-
pared to those from low- and middle-income countries
(β� −0.803, 95% CI: −1.23 to −0.38; P≤ 0.001; Figure 3(b)).
However, there was a moderate positive relationship be-
tween subregion and pooled prevalence of herbal medicine
use in cancer, with certain subregions being more likely than
others to report a high prevalence of the use of herbal
medicine in cancer (β� 0.134, 95% CI: 0.005–0.264;
P � 0.043).
3.5. Specific Pooled Prevalence by Study Subpopulation
3.5.1. Pooled Prevalence of Herbal Medicine Use by Children
with Cancer. In total, the crude prevalence estimates of
herbal medicine use by children with cancer was reported by
23 studies [30, 37, 40, 63, 82, 102, 106, 108, 118,
119, 121, 126, 132–135, 137, 143, 146, 151, 157, 165]. )e
Table 2: Characteristics of included studies (n� 155).
Variable Mean± standard deviationor n (%)
Female (n� 96) 53.95± 14.04
Age, years (n� 86) 50.98± 17.39
Response rate (n� 99) 76.95± 19.78









Subregion (World Bank category)
Europe and Central Asia 51 (32.92)
North America 47 (30.32)
East Asia and Pacific 36 (23.23)
Middle East 13 (8.39)
Latin America and the Caribbean 5 (3.23)
Sub-Saharan Africa 3 (1.94)
Income (World Bank category)
Low/middle income 51 (34.23)
High income 98 (65.77)















Herbal medicine only 12 (7.74)
Study setting
Hospital (e.g., cancer clinic,
institute, center, unit) 133 (85.81)
Cancer/tumor registry 6 (3.87)

















Variable Mean± standard deviationor n (%)
Researcher-administered
interview (telephone, in-person) 59 (38.06)
Record/document review 6 (4.11)




Mixed (several types) 113 (72.90)
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prevalence estimates ranged from 1% (95% CI: 0%–5%) to
71% (95% CI: 61%–79%). With one exception, these studies
were conducted in America and Europe. )e overall ran-
dom-effects pooled prevalence of herbal medicine use by
children with cancer was 18% (95% CI: 11%–27%; Figure 4).
)e I2 statistic was 95.75% (χ2 (df� 22)� 517.11; P≤ 0.001),
suggesting considerable heterogeneity among the included
studies. Egger’s regression test confirmed that the funnel plot
was asymmetrical (P≤ 0.001), raising the possibility of
small-study effects (publication bias).
Across income groups, low- and middle-income coun-
tries (33%, 95% CI: 16%–52%) were more likely to have a
high prevalence of herbal medicine use by children with
cancer than high-income countries (12%, 95% CI: 7%–18%).
In terms of continents, Europe (18%, 95% CI: 7%–34%) and
America (18%, 95% CI: 10%–28%) had a similar prevalence
of herbal medicine use by children with cancer. Children
with hematological cancers (7%, 95% CI: 2%–16%) were less
likely to report the use of herbal medicine in cancer than
those with all other cancer types combined (20%, 95% CI:
12%–30%).
Subgroup analyses indicated that the income group
(P � 0.02), data collection method (P � 0.01), type of cancer
(P � 0.03), and study period (P � 0.02) had significant
moderating effects on the pooled prevalence of the use of
herbal medicine in cancer. However, the meta-regression
analysis showed that only three variables were statistically
significant moderators of the pooled prevalence of herbal
medicine usage in cancer. )e income group was negatively
related to the pooled prevalence of usage of herbal medicine
in cancer, with studies from high-income countries less







Europe 47 18 (14, 22)
Asia 46 28 (21, 35)
Africa 3 40 (23, 58)
America 53 21 (17, 25)
Oceania 6 9 (4, 15)
Subregion
Europe and Central asia 51 19 (15, 23)
East Asia and Pacific 36 21 (14, 29)
N. America 47 20 (16, 24)
Sub-Saharan Africa 3 40 (23, 58)
Middle east 13 36 (19, 54)
L. America and Carribean 5 35 (23, 48)
Income
Low/Middle 51 32 (23, 43)
High income 98 17 (14, 21)
Country (n ≥ 3 studies)
Palestine 4 69 (59, 77)
China 7 58 (45, 71)
Turkey 18 33 (22, 44)
Taiwan 7 24 (9, 42)
Canada 5 21 (11, 33)
South Korea 3 21 (7, 40)
USA 42 19 (15, 24)
Germany 5 12 (6, 19)
ailand 3 12 (0, 38)
Malaysia 5 10 (5, 17)
UK 9 8 (3, 14)
Australia 5 8 (2, 16)
Mixed European countries 6 15 (11, 18)
Study Focus
Herbal medicine Only 12 48 (35, 61)
CAM 143 20 (16, 23)
Study design
Cross-sectional 154 22 (18, 25)
Cohort 1 42 (38, 46)
Overall 155 22 (18, 25)
Prevalence of herbal medicine use (%)
0 20 40 60 80 100
Figure 2: A summary (subgroup) forest plot on herbal medicine usage in cancer.
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medicine by children with cancer than those from low- and
middle-income countries (β� −1.263 95% CI: −2.317395
to −0.208673; P � 0.021). In addition, the use of herbal
medicine was less likely to be reported in studies conducted
between 2011 and 2020 (11%, 95% CI: 4%–19%) than those

















































Figure 3: Meta-regression of herbal medicine use by study focus (a) and country income level (b), respectively.
Subgroup Studies (n) Prevalence (95% CI)
Income
Middle 9 33.00 (15.00, 52.00)
High 14 12.00 (7.00, 18.00)
Region  
Europe 10 18.00 (7.00, 34.00)
America 13 18.00 (10.00, 28.00)
Year  
2000–2010 12 27.00 (16.00, 39.00)
2011–2020 11 11.00 (4.00, 19.00)
Study type  
Self report 12 10.00 (3.00, 20.00)
Researcher administered 11 29.00 (20.00, 39.00)
Cancer type  
Heamatological 3 7.00 (2.00, 16.00)
Mixed 20 20.00 (12.00, 30.00)
Overall  
Overall sample 23 18.00 (11.00, 27.00)
0 10 20 30 40 50 60
Prevalence of herbal medicine use (%)
Figure 4: A summary (subgroup) forest plot on herbal medicine usage among children with cancer.
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β� −1.19, 95% CI: −2.22 to −0.15; P � 0.027). However,
studies that used researcher-administered data collection
instruments (29%, 95% CI: 20%–39%) tended to report a
high pooled prevalence of herbal medicine use by children
with cancer than those that were self-administered (10%,
95% CI: 3%–20%; β� 1.38967, 95% CI: 0.418–2.36;
P � 0.007).
3.5.2. Pooled Prevalence of Herbal Medicine Use by Adult
Patients with Cancer. Overall, 130 studies (that met the
eligibility criteria) were incorporated in the meta-analysis of
the prevalence of herbal medicine usage by adult patients
with cancer [3–12, 14–29, 31–36, 38, 39, 55–59, 61,
62, 64–81, 83–101, 103–105, 107, 109–117, 120, 122–125,
127–131, 134, 136, 138–142, 144, 145, 147–150,
152–156, 158–164, 166–168]. )e lowest crude prevalence
was 1% (95% CI: 0%–1%) and the highest was 86% (95% CI:
78%–92%).
)e random-effects pooled prevalence of the usage of
herbal medicine by adults with cancer was 23% (95% CI:
17%–29%; Figure 5). )e I2 statistic was 99.96% (χ2
(df� 129)� 309703.50; P≤ 0.001), demonstrating consider-
able heterogeneity among the included studies. )e funnel
plot was symmetrical as confirmed by Egger’s regression test
(P � 0.220), suggesting there were no small-study effects
(publication bias).
)e highest pooled prevalence of the usage of herbal
medicine in adults with cancer was in Africa (47%, 95% CI:
42%–53%), followed by Asia (30%, 95% CI: 19%–42%),
America (21%, 95% CI: 17%–26%), Europe (18%, 95% CI:
14%–22%), and Oceania (9%, 95% CI: 4%–15%). In terms
of subregions, the highest prevalence of herbal medicine
use among adults with cancer was in sub-Saharan Africa
(47%, 95% CI: 42%–53%), followed by the Middle East
(36%, 95% CI: 15%–60%), East Asia and the Pacific (24%,
95% CI: 13%–37%), North America (21%, 95% CI: 17%–
26%), and Europe and Central Asia (19%, 95% CI: 15%–
23%). Across income groups, adults with cancer from low-
and middle-income countries (33%, 95% CI: 22%–44%)
were more likely to report a high prevalence of herbal
medicine than those in high-income countries (19%, 95%
CI: 13%–26%).
)e subgroup analyses indicated that study country
(P≤ 0.001), study focus (P≤ 0.001), study region (P≤ 0.001),
study design (P≤ 0.001), income group (P � 0.02), and
study subregion (P≤ 0.001) were statistically significant
moderators of the pooled prevalence of herbal medicine
usage by adults with cancer. However, bivariate meta-re-
gression revealed that only study focus and income group
had negative relationships with the pooled prevalence.
Studies that focused on herbal medicine along with other
CAM modalities (21%, 95% CI: 15%–27%; β� −1.506, 95%
CI: −2.25 to −0.76; P≤ 0.001) and those from high-income
countries (β� −0.75, 95%CI: −1.23 to −0.27;P � 0.002) were
less likely to report a high pooled prevalence of herbal
medicine use in adults with cancer than studies that focused
on herbal medicine alone (49%, 95%CI: 34%–64%) and were
from low- and middle-income countries.
3.6. Specific Pooled Prevalence by Gender
3.6.1. Pooled Prevalence of Herbal Medicine Use by Male
Patients with Cancer. Twelve studies reported crude prev-
alence estimates of the use of herbal medicine among male
patients with cancer [71, 76, 88, 90, 97, 101, 112–114,
152, 161, 167]. All of these studies were conducted among
patients with prostate cancer in the Americas and Asia. )e
crude prevalence ranged from 1% (95% CI: 0%–7%) to 76%
(95% CI: 75%–76%). )e overall random-effects pooled
prevalence of the use of herbal medicine by male patients
with cancer was 17% (95% CI: 1%–47%; Figure 6). )e I2
statistic was 99.98% (χ2 (df� 22)� 44251.66; P≤ 0.001),
representing significant heterogeneity among the included
studies. )e funnel plot was symmetrical as confirmed by
Egger’s regression test (P � 0.064), indicating the absence of
small-study effects (publication bias).
)e continent of Asia (23%, 95% CI: 0%–80%) had a
higher prevalence of the male patients with cancer who used
herbal medicine compared with America (13%, 95% CI: 8%–
20%). Subgroup analyses indicated that only the study pe-
riod (P≤ 0.001) had a statistically significant moderating
effect on the overall pooled prevalence of the use of herbal
medicine among male patients with cancer. Contrariwise,
the meta-regression analysis showed that this relationship
was weak, with studies conducted between 2011 and 2020
(74%, 95% CI: 74%–75%) more likely to report a high
prevalence of the use of herbal medicine by male patients
with cancer than those conducted between 2000 and 2010
(11%, 95% CI: 7%–16%; β� 2.06, 95% CI: −0.002 to 4.13;
P � 0.050).
3.6.2. Pooled Prevalence of Herbal Medicine Use by Female
Patients with Cancer. )e prevalence of herbal medicine
usage in female patients with cancer was reported in 35
studies [9, 10, 18, 24, 27, 28, 38, 55, 61, 64, 73, 83–85,
87, 90, 93, 95, 100, 110, 115, 123, 125, 138, 141, 145, 147,
149, 154, 155, 159, 163, 164, 166, 168]. With one exception,
these studies were conducted in Asia, America, and Europe.
)e lowest prevalence of female patients with cancer using
herbal medicine was 3% (95% CI: 2%–5%) and the highest
was 85% (95% CI: 82%–87%). )e random-effects pooled
prevalence of the usage of herbal medicine by female patients
with cancer was 27% (95% CI: 19%–35%; Figure 7). )e I2
statistic was 99.63% (χ2 (df� 34)� 9133.34; P≤ 0.001)
reflecting considerable heterogeneity among the included
studies. )e funnel plot was symmetrical as confirmed by
Egger’s regression test (P � 0.967P � 0.967), indicating the
absence of small-study effects (publication bias).
Among continents, the highest prevalence of the use of
herbal medicine by female cancer patients was in Asia (31%,
95% CI: 16%–48%) followed by America (27%, 95% CI:
19%–36%) and Europe (22%, 95% CI: 11%–37%). )e
Middle East subregion (31%, 95% CI: 4%–69%) had the
highest prevalence of the use of herbal medicine by female
patients with cancer, followed by North America (27%, 95%
CI: 19%–36%), East Asia and the Pacific (26%, 95% CI: 10%–
48%), and Europe and Central Asia (25%, 95% CI: 14%–
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37%). A higher pooled prevalence of herbal medicine usage
among female patients was recorded in low- and middle-
income countries (34%, 95% CI: 14%–58%) compared with
high-income countries (24%, 95% CI: 18%–30%). Similarly,
studies involving patients with other cancers combined
(28%, 95% CI: 14%–44%) tended to report a higher prev-
alence of herbal medicine usage among female patients with
cancer than studies that focused on breast cancer alone
(26%, 95% CI: 18%–36%).
)e subgroup analysis showed that the study focus
(P≤ 0.001) and study region (P≤ 0.001) had a statistically
significant moderating effect on the overall pooled preva-
lence of the use of herbal medicine among female patients
with cancer. However, in the meta-regression analysis, only
study focus had a weak negative relationship with the pooled
prevalence of herbal medicine use in cancer. Studies that
focused on herbal medicine along with other CAM mo-
dalities (25%, 95% CI: 17%–33%; β� −1.634, 95% CI:
−3.49–0.220; P � 0.082; Figure 7) were less likely to have a
high pooled prevalence than studies that focused on herbal
medicine use in cancer alone (63%, 95% CI: 55%–71%).
3.7. Herbs Used and Reported by Patients with Cancer. In
total, 86 studies reported herbs most commonly used in
cancer, which included the following: evening primrose
(Oenothera biennis), Echinacea (Echinacea purpurea), garlic
(Allium sativum), stinging nettle (Urtica dioica), garden
thyme ("ymus vulgaris), black cumin (Nigella sativa), green
tea (Camellia sinensis), ginseng (Panax ginseng), ginger
(Zingiber officinale), flaxseed (Linum usitatissimum), myrtle
(Myrtus communis), ginkgo (Ginkgo biloba), aloe vera (Aloe
barbadensis), St. John’s wort (Hypericum perforatum), Essiac
(containing four herbs: sorrel, slippery elm, Turkey rhubarb,
and burdock), garden sage (Salvia officinalis), rosehip (Rosa
canina), rosemary (Rosmarinus officinalis), turmeric (Cur-
cuma longa), peppermint (Mentha piperita), Sabah snake
grass (Clinacanthus nutans), kava kava (Piper methysticum),
Subgroup Studies (n) Prevalence (95% CI)
Region
Europe 37 18.00 (14.00, 22.00)
Asia 44 30.00 (19.00, 42.00)
Africa 2 47.00 (42.00, 53.00)
America 41 21.00 (17.00, 26.00)
Oceania 6 91.00 (4.00, 15.00)
Subregion
Europe and central asia 42 19.00 (15.00, 23.00)
East asia and pacific 35 24.00 (13.00, 37.00)
N.America 39 21.00 (17.00, 26.00)
Sub-Saharan africa 2 47.00 (42.00, 53.00)
Middle east 11 36.00 (15.00, 60.00)
L. America and carribean 1 37.00 (32.00, 42.00)
Income
Middle 40 33.00 (22.00, 44.00)
High income 84 19.00 (13.00, 26.00)
Study focus  
Herbal medicine only 11 49.00 (34.00, 64.00)
CAM 119 21.00 (15.00, 27.00)
Study design  
Cross-sectional 129 23.00 (17.00, 29.00)
Cohort 1 42.00 (38.00, 46.00)
Overall sample  
Overall 130 23.00 (17.00, 29.00)
0 10 20 30 40 50 60 70
Prevalence of herbal medicine use (%)
Figure 5: A summary (subgroup) forest plot on herbal medicine usage among adult patients with cancer.
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chamomile (Matricaria chamomilla), mistletoe (Viscum
album), soy products (Glycine max), wild Hedyotis diffusa,
barbed skullcap (Scutellaria barbata), noni (Morinda cit-
rifolia), grape seed extract (Vitis vinifera), grapefruit (Citrus
paradisi), milk thistle (Silybum marianum), French lavender
(Lavendula stoechas), senna (Cassia acutifolia), licorice root
(Glycyrrhiza glabra), cinnamon (Cinnamonum zeylanicum),
snakehead (Chana striata), blackberry (Rubus caesius), saw
palmetto (Serenoa repens), and wormwood (Artemisia
absinthium). Other herbs that were less commonly used but
Subgroup Studies (n) Prevalence (95% CI)
Region
Europe 7 22 (11, 37)
Asia 14 31 (16, 48)
America 13 27 (19, 36)
Subregion
Europe and central asia 10 25 (14, 37)
East asia and pacific 9 26 (10, 48)
Middle east 3 31 (4, 69)
North america 13 27 (19, 36)
Income
Middle 11 34 (14, 58)
High 22 24 (18, 30)
Study focus  
Herbal medicine only 2 63 (55, 71)
CAM 33 25 (17, 23)
Cancer type∗  
Breast 29 26 (18, 36)
Mixed 6 28 (14, 44)
Overall 35 27 (19, 35)
0 20 40 60
Prevalence of herbal medicine use (%)
Figure 7: A summary (subgroup) forest plot on herbal medicine usage among female patients with cancer.
Subgroup Studies (n) Prevalence (95% CI)
Region  
America 8 13.00 (8.00, 20.00)
Asia 4 23.00 (0.00, 80.00)
Year  
2000–2010 10 11.00 (7.00, 16.00)
2011–2020 2 74.00 (74.00, 75.00)
Overall sample  
Overall 12 17.00 (1.00, 47.00)
0 10 20 30 40 50 60 70 80 90
Prevalence of herbal medicine use (%)
Figure 6: A summary (subgroup) forest plot on herbal medicine usage among male patients with cancer.
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reported by patients with cancer are listed in Supplementary
Table 6.
4. Discussion
It has become increasingly common to base healthcare
decision-making on information obtained from evidence-
based medicine. Previously, this information was obtained
from systematic reviews of interventional studies. However,
this evidence is now also being acquired from systematic
reviews of observational studies. )e present review inves-
tigated the prevalence of the herbal medicine use among
patients with cancer to inform and guide the development of
healthcare policies concerning integrating herbal medicine
in clinical cancer care.
)is review suggested that a large estimated percentage
of cancer patients use herbal medicine, especially during
conventional treatment. )e overall pooled prevalence of
herbal medicine usage by patients with cancer was 22% (95%
CI: 18%–25%), which means approximately one in five
patients with cancer used herbal medicine(s) following a
cancer diagnosis. )is finding was consistent with the lit-
erature, where herbal medicine was reported as the leading
form of CAMused in cancer [4–6, 8, 11, 12, 114].)is review
also found that Africa and Asia had the highest pooled
prevalence of the usage herbal medicine in cancer, with the
lowest prevalence recorded in Oceania. Similarly, a larger
percentage of patients with cancer from low- and middle-
income countries used herbal medicine compared with those
from high-income countries. )is trend was repeated across
specific subpopulations of children, adults, and female pa-
tients with cancer.)e variation in prevalence across regions
may be explained by variances in geographical character-
istics (i.e., conditions that make some herbs easily available),
cultural beliefs and attitudes, and liberalized or low regu-
lation of herbal medicines [18–20, 31, 79, 131, 139, 162].
Conversely, the high herbal medicine usage in low- and
middle-income countries might possibly be because of the
low income levels, whichmaymean that patients with cancer
are unable to pay for conventional cancer care (financial
constraints) and or due to deeply rooted cultural practices
related or favorable to use of herbal medicines. For example,
as shown in this study, Asian countries such as South Korea
and Taiwan, despite having the conditions and economic
power to receive high-quality conventional therapies, pa-
tients from these countries still continue to use herbal
medicine while accepting conventional therapies. Above all,
high-income countries (of North America and Europe)
where most studies included in this review were conducted
do not possess a specialized or deeply ingrained traditional
medicine use culture compared to countries of Asia and
Africa.
)e findings of this review suggested that compared to
children (with cancer), adult patients with cancer were more
likely to use herbal medicine, although this difference was
not statistically significant. )is variance in prevalence may
be related to adults having more freedom to use herbal
medicine than children who generally depend on their
parents to access such products [106]. However, given the
physiological nature of children (i.e., immaturity of organs
such as the liver) and the potential risks of herbal medicine
for children as reported in previous studies, parents need to
make informed decisions based on evidence-based infor-
mation before administering herbal medicine to their
children to protect children from possible harmful effects
[37].
We also found that more female patients with cancer
compared to their male counterparts used herbal medicine.
However, the pooled prevalence of the use of herbal med-
icine by male patients with cancer was from studies con-
ducted among patients with prostate cancer; therefore, that
reported prevalence best represents herbal medicine usage
among patients with prostate cancer. Similarly, most studies
that focused on female patients with cancer included pa-
tients with breast cancer, although the use of herbal med-
icine was higher in breast cancer than prostate cancer. )ese
gender-based findings concur with previous literature,
where the use of herbal medicine in cancer was related to
being female, with women more likely to use herbal med-
icine as a primary mode of healthcare thanmen [22, 23, 138].
Finally, this review revealed several herbs commonly
used in cancer, some with proven evidence of beneficial
effects (anticancer effects) and others with potential risks
(harmful side effects and drug interactions) to patients.
)ose with possible detrimental effects to patients included
garlic, ginseng, kava, and St. John’s wort [31, 32, 35]. Given
that most of the studies that reported use of those herbs were
conducted among cancer patients who were receiving
conventional cancer therapies, clinicians (oncologists)
should ask about herbal medicine use during their routine
care of such patients.
4.1. Implications and Recommendations. Regardless of var-
iation in the level of herbal medicine regulatory frameworks
in different countries across the world, the high percentage
of the usage of herbal medicine reported by this study calls
for some form of integration of herbal medicine into cancer
care. Healthcare providers must be at the center of this
integration. )e lack of sufficient clinical evidence should
not be a deterrent to this integration, although health
practitioners at all levels of patient care should routinely ask
about, offer, and document evidence-based advice to pa-
tients with cancer on the safety and possible benefits of herbs
and herb-drug interactions. Routine discussion of these
issues during cancer screening, treatment, and follow-up
may help to improve patient care outcomes. However, to
equip health workers with evolving evidence on herbal
medicines used in cancer, health educators need to continue
incorporating knowledge about herbal medicines in onco-
logical care training curricula and also develop programs
geared toward understanding, evaluating, and validating
herbal medicine use in cancer. In the short-term, health
managers could develop short courses or refresher training
for in-service healthcare workers on herbal medicines used
in cancer to improve their knowledge on this subject.
In addition, policy makers at national governmental and
international levels, such as drug authorities and health
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ministries, should incorporate and update new evidence
regarding herbal medicine into oncology treatment guide-
lines, standard operating procedures, patient charts or
electronic medical records, and pharmacopeias. )is will
assist healthcare workers to document herbal medicine
practices in clinical care, which will subsequently promote
clinical research on herbal medicine use in cancer.
As evidence regarding herbal medicine continues to
evolve, policy makers in countries that regulate herbal
medicine as dietary supplements or do not regulate herbal
medicine at all need to update, review, or change their herbal
medicine regulatory frameworks (either entirely or on a
case-by-case basis) to protect patients with cancer from
possible harmful effects posed by some herbs. In addition, as
the media and other informal sources of information on
herbal medicine are responsible for the high use of herbal
medicine by cancer patients, oncology care centers and
policy makers could create official websites or other media
platforms with authentic and updated information on
commonly or locally available herbal medicines to counter
the misinformation from other sources. )ese platforms
may be communicated to patients during routine cancer
care. Importantly, these platforms should encourage patients
to always seek advice regarding their specific circumstances
from a qualified healthcare professional.
Successful integration of herbal medicine into cancer
care either as an alternative form of medicine or alongside
cancer medicine requires further high-quality multidisci-
plinary research on herbal medicines used in cancer, which
requires research funding. )erefore, policy makers need to
advocate, fundraise, and allocate resources for cancer re-
search concerning herbal medicine use. For example, the
lack of funding for research on herbal medicinesmay explain
the relatively few published studies on herbal medicine in
cancer, especially in Africa and South America, as observed
in this study. In addition, it is important to note that in this
study, we were unable to conduct a meta-analysis of the
usage of herbal medicine in cancer across many other pa-
tients’ characteristics due to inconsistent study variables.
)erefore, it is necessary to develop a standardized survey
tool customizable to various patients with cancer and set-
tings to measure herbal medicine use in cancer. Such a tool
will allow comprehensive systematic reviews to be con-
ducted on this subject. It is also necessary to conduct more
herbal medicine-specific observational research in cancer to
obtain extensive statistics on the extent of herbal medicine
usage in cancer across the world.
4.2. Limitations and Strengths of "is Study. In terms of the
quality of included studies, we rated the majority of studies
as having a moderate to high risk of bias, which might have
led to over- or underestimation of the pooled prevalence of
herbal medicine use reported in this study.)is was expected
given that nearly all studies used cross-sectional designs.
However, the majority of the included studies had mod-
erately large sample sizes and high response rates. Second,
there was a high proportion of heterogeneity (between-study
heterogeneity) associated with the estimated pooled
prevalence(s) reported in this study. However, this was
minimized through estimating the pooled prevalence using a
random-effects model and performing extensive subgroup
and meta-regression analyses. )ird, we acknowledge the
limited number of studies from sub-Saharan Africa, and the
pooled estimate from the few available studies might be
overestimated. However, this provides an opportunity for
further research on usage of herbal medicine among patients
with cancer in Africa. Fourth, we only included studies
published in the English language (thus missing studies
published in other languages, particularly from the Fran-
cophone or Portuguese speaking countries) and did not
include grey literature (dissertations or conference ab-
stracts), which might have affected the outcomes (pooled
prevalence rates) reported. Nonetheless, based on exami-
nation of the funnel plots and use of Egger’s test of funnel
plot asymmetry, no evidence of small-study effects (publi-
cation bias) was observed (found) across a sample of primary
studies included in this study; therefore, the results of this
review are unlikely to reflect bias. )e majority of the in-
cluded primary studies were prospective, and sufficient time
was invested in these studies, making their results somewhat
reliable. Finally, this study provides a strong point of ref-
erence for future studies, as it is one of the first reviews to be
conducted on the prevalence of the use of herbal medicine
amongst cancer patients.
5. Conclusion
)is systematic review shows that a large percentage of
patients with cancer use herbal medicine, especially those
from low- and middle-income countries. In addition, larger
percentages of adult patients with cancer (compared with
children) and female patients with cancer (compared with
males) used herbal medicine. In summary, there is need for
additional epidemiological investigations exploring herbal
medicine integration into cancer care especially for low- and
middle-income countries.
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